CD4 and graft versus host disease: Type I IFNs were shown to interpose the processes of graft-versus-leukemia (GVL) and graft-versus-host disease (GVHD) by reducing alloreactive donor T-cell expansion, thus providing protection from CD4-dependent GVHD [275].